Companies · Biotechnology

Camp4 Therapeutics Corp

CAMBRIDGE · Biotechnology

Diligence memoA one-page analyst read on Camp4 Therapeutics Corp — recommendation, valuation, rhythm, risks.
$179.6M
Total raised · real
3
Rounds
6.7×
Latest step-up
Top 5%
Sector rank · raised
Series D+
Latest stage · inferred · Fri Jun 03 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Camp4 Therapeutics Corp looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.09× the median modeled value of Series D+ Biotechnology companies in 2022–2024 (75 peers) — value vs value, same stage and era.
  • Within the normal band (109% of peer median) for its niche.
Dormant
  • Last raise 4.1 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Camp4 Therapeutics Corp is one of 4293 Biotechnology companies tracked from CAMBRIDGE. By capital raised it ranks among the largest (ahead of 96% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

pharma

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
16
Investors (latest)
2022-06-03
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$1.3B$2.5B$3.8B$5.0BSeries B · 2018-04-20 Raised $34M (real) Modeled valuation $1.4B (est)$34M$1.4BSeries B2018Series C · 2021-03-05 Raised $45M (real) Modeled valuation $1.4B (est)$45M$1.4BSeries C2021Series A · 2021-03-05 Raised $15M (real) Modeled valuation $392M (est)$15M$392MSeries A2021Series D+ · 2022-06-03 Raised $100M (real) Modeled valuation $2.2B (est)$100M$2.2BSeries D+2022+$45M+$15M+$100MCumulative $195M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series B$34.1M · 2018
Series C$45.0M · 2021
Bridge · Series C-stage$15.0M · 2021smaller follow-on
Series D+$100.5M · 2022

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$2.2B
Base estimate est.
$455.6M
Conservative case
$3.9B
Upside case
$837.5M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series D+a $100M–$400M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series B · modeled $1.4B · 2018-04-202018Series C · modeled $1.4B · 2021-03-05Series A · modeled $391.6M · 2021-03-05Series D+ · modeled $2.2B · 2022-06-032022
Model inputs · modeled:benchmark-stage-stepup-v1
12%
Dilution assumption
Implied ownership sold in the financing.
68%
Survival probability
54% low · 75% high
1.39×/yr
Annual markup
1.56×/yr upside case
4.1 yr
Elapsed time used
4.1 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
16 mo
Avg between rounds
$43.6M/yr
Capital velocity
8.2 yr
On record since
2018
First round
4
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 25× above median
This company$179.6M
Sector median$7.2M
Latest round — vs other Series D+ rounds in sector (real $, this stage) 0.8× of median
This company$100.5M
Sector median$120.0M
Modeled value — vs sector median (estimate, all stages) 34× above median
This company$2.2B
Sector median$64.2M

Raised more than 96% of sector peers (real $). Modeled value above 95% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series D+) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #35 of 75.

This companyCohort peer
$1.0B$10.0B$100.0M$1.0BCapital raised (log)Areteia Therapeutics, Inc. · Series D+ Raised $360.0M · modeled $7.8B (est)GIO World Health Ltd · Series D+ Raised $300.0M · modeled $7.4B (est)Crinetics Pharmaceuticals, Inc. · Series D+ Raised $428.0M · modeled $4.3B (est)2seventy bio, Inc. · Series D+ Raised $170.0M · modeled $4.0B (est)Gio World Health (Europe) Sa · Series D+ Raised $150.0M · modeled $3.7B (est)GIO World Health (Europe) Ltd · Series D+ Raised $150.0M · modeled $3.7B (est)Arsenal Biosciences, Inc. · Series D+ Raised $579.2M · modeled $3.5B (est)ImmPACT Bio USA Inc. · Series D+ Raised $143.6M · modeled $3.5B (est)BioNTech SE · Series D+ Raised $400.0M · modeled $3.4B (est)RayzeBio, Inc. · Series D+ Raised $396.4M · modeled $3.4B (est)Genesis Therapeutics, Inc. · Series D+ Raised $297.4M · modeled $3.3B (est)Legend Biotech Corp · Series D+ Raised $350.5M · modeled $3.3B (est)Camp4 Therapeutics Corp (this company) Raised $179.6M · modeled $2.2B (est)Camp4 Therapeutics Corp
CompanyStageRaised · realValue · estvs peer med.
Areteia Therapeutics, Inc.Series D+$360.0M$7.8B3.87×
GIO World Health LtdSeries D+$300.0M$7.4B3.67×
Crinetics Pharmaceuticals, Inc.Series D+$428.0M$4.3B2.13×
2seventy bio, Inc.Series D+$170.0M$4.0B1.98×
Gio World Health (Europe) SaSeries D+$150.0M$3.7B1.84×
GIO World Health (Europe) LtdSeries D+$150.0M$3.7B1.84×
Arsenal Biosciences, Inc.Series D+$579.2M$3.5B1.76×
ImmPACT Bio USA Inc.Series D+$143.6M$3.5B1.72×
BioNTech SESeries D+$400.0M$3.4B1.71×
RayzeBio, Inc.Series D+$396.4M$3.4B1.69×
Genesis Therapeutics, Inc.Series D+$297.4M$3.3B1.64×
Legend Biotech CorpSeries D+$350.5M$3.3B1.63×
Camp4 Therapeutics Corp this companySeries D+$179.6M$2.2B1.09×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series B$34.1M2018-04-20$189.3M$1.4B90%
Series C$45.0M2021-03-05$300.0M$1.4B90%
Series A$15.0M2021-03-05$68.2M$391.6M90%
Series D+$100.5M2022-06-03$837.5M$2.2B90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series B$34.1M2018-04-20
    • First recorded raise — entered as Series B.
    • 6 investors on this round.
  2. Series C$45.0M2021-03-05
    • Raised again after 34 mo — slower than the ~14 mo sector norm.
    • Round 1.3× larger than the prior — scaling up.
    • 7 investors on this round.
  3. Series A$15.0M2021-03-05
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 3.0× smaller than the prior — bridge or down round.
    • 7 investors on this round.
  4. Series D+$100.5M2022-06-03
    • Raised 15 mo later, in step with the ~14 mo sector norm.
    • Round 6.7× larger than the prior — scaling up.
    • 16 investors on this round.
Intelligence
2023 ~Q4
Modeled next raise · ~16mo cadence
$301.5M
Modeled next size est.range $196.0M$482.4M
6.7×
Last step-up
$43.6M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Amir Nashat13 other2018-04
Michael Higgins8 other2018-04
Andrew J. Schwab6 other2022-06
Jorge Conde3 other2018-04
Shaan Gandhi3 other2021-03
Paula Ragan2 other2021-03
Andy Schwab1 other2021-03
ANN BARBIER1 other2022-06
Shaan I Gandhi1 other2022-06
ALFICA SEHGAL2021-03
CALEB MOORE2021-03
DAVID BUMCROT2021-03
JAMES J. BOYLAN2022-06
JOSH MANDEL-BREHM2018-04
KELLY GOLD2021-03
MICHELLE GATES2021-03
RAVI I. THADHANI2022-06
RAVI THADHANI2021-03
RICHARD YOUNG2018-04
STEVE HOLTZMAN2021-03
Registry & provenance

Camp4 Therapeutics Corp is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1736730
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Syros Pharmaceuticals, Inc.BiotechnologySeries D+$296.1M$2.6Bnetwork2 shared operators · same sector · same stage
Morphic Holding, Inc.BiotechnologySeries C$200.6M$1.5Bnetwork1 shared operator · same sector
Garuda Therapeutics, Inc.BiotechnologySeries C$158.0M$380.2Mnetwork1 shared operator · same sector
Genocea Biosciences, Inc.BiotechnologySeries C$153.6M$3.0Bnetwork1 shared operator · same sector
Avalo Therapeutics, Inc.BiotechnologySeries D+$181.8M$1.6Bsame sector · same stage
Tune Therapeutics, Inc.BiotechnologySeries D+$182.4M$3.1Bsame sector · same stage
SAB Biotherapeutics, Inc.BiotechnologySeries D+$182.5M$1.4Bsame sector · same stage
Aktis Oncology, Inc.BiotechnologySeries D+$175.0M$1.8Bsame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
4e Therapeutics, Inc.BiotechnologySeed$40.4M86%
4D Molecular Therapeutics IncBiotechnologySeries C$3.7B84%
S4 Medical Corp.BiotechnologySeries A$49.6M83%
MedGene Therapeutics, Inc.BiotechnologySeed$28.8M83%
X4 Pharmaceuticals, IncBiotechnologySeries C$495.3M83%
Grid Therapeutics LLCBiotechnologySeries A$19.9M82%
Dev4 LLCBiotechnologySeed$4.0M82%
Genesis Therapeutics, Inc.BiotechnologySeries D+$3.3B82%
Frequently asked
How much funding has Camp4 Therapeutics Corp raised?
Camp4 Therapeutics Corp has raised approximately $179.6M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Camp4 Therapeutics Corp's estimated valuation?
Provath's modeled valuation for Camp4 Therapeutics Corp is approximately $2.2B (modeled range $455.6M–$3.9B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Camp4 Therapeutics Corp at?
Camp4 Therapeutics Corp's latest modeled financing stage is Series D+. Its most recent recorded round closed around Fri Jun 03.
What does Camp4 Therapeutics Corp do and where is it based?
Camp4 Therapeutics Corp operates in the Biotechnology sector, based in CAMBRIDGE.
Explore related

See where Camp4 Therapeutics Corp sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Camp4 Therapeutics Corp, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.